Metabolic Health Consequences of Switching to the Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir Plus Lamivudine Regimens in Virologically Suppressed People Living with HIV Aged > 40 Years: A Retrospective Real-World Study
In this study, the B/F/TAF or DTG/3TC regimens are safe for virologically suppressed PLWH aged > 40 years. The transition to B/F/TAF demonstrated dual clinical benefits, significantly reducing hyperglycemia incidence while preserving renal function.
Authors
- Dingyan Yan
- Wenhui Zhang (ORCID: https://orcid.org/0000-0003-4504-6101)
- Feng Li (ORCID: https://orcid.org/0000-0002-4853-2255)
- Jie Han (ORCID: https://orcid.org/0000-0002-8617-3708)
- Jinchuan Shi (ORCID: https://orcid.org/0000-0003-2582-2660)
- Rongrong Zheng (ORCID: https://orcid.org/0000-0002-1686-807X)
- Zhongdong Zhang
- Yi Wang (ORCID: https://orcid.org/0000-0001-9081-120X)
Institutions
- Zhejiang Chinese Medical University (CN)
- Hangzhou Xixi hospital (CN)
Publication Details
- Journal
- Infection and Drug Resistance
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/idr.s516775
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00